# A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

> **NCT04632992** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 252 (actual)

## Conditions studied

- Advanced Unresectable or Metastatic Solid Malignancy

## Interventions

- **DRUG:** Entrectinib
- **DRUG:** Inavolisib
- **DRUG:** Alectinib
- **DRUG:** Ipatasertib
- **DRUG:** Atezolizumab
- **DRUG:** Trastuzumab Emtansine
- **DRUG:** Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
- **DRUG:** Tucatinib
- **DRUG:** Investigator's Choice of Chemotherapy
- **DRUG:** Paclitaxel
- **DRUG:** Tiragolumab
- **DRUG:** Pralsetinib

## Key facts

- **NCT ID:** NCT04632992
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-13
- **Primary completion:** 2023-12-04
- **Final completion:** 2024-02-27
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2025-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632992, "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04632992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*